Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- 1 April 2016
- journal article
- Published by Elsevier BV in Annals Of Oncology
- Vol. 27 (4), 732-738
- https://doi.org/10.1093/annonc/mdw016
Abstract
Background Clinical responses to ipilimumab are variable in terms of onset, magnitude and duration. Upfront identification of patients who are more likely or unlikely to benefit from treatment is a major need. Patients and methods Prospectively collected data from 720 advanced melanoma patients treated with ipilimumab 3 mg/kg within the Italian expanded access programme were analyzed. The derived neutrophil-to-lymphocyte ratio (dNLR) was calculated from baseline peripheral blood cell counts, and receiver operating characteristic curve was used to evaluate the best cut-off for this marker. Patients were stratified according to dichotomized baseline absolute neutrophil counts (ANC), dNLR, and their combination. The prognostic values of ANC and dNLR for survival were assessed using multivariate Cox proportional hazard models. A subgroup analysis including LDH in the models was also performed. Results The median follow-up was 16.5 months. The optimal cut-off for dNLR was 3. Baseline ANC and dNLR were significantly associated with outcome of ipilimumab-treated melanoma patients, in terms of disease progression and death (PConclusions Although these findings need to be confirmed and validated, we suggest that a neutrophil-based index may help risk-group stratification and assist disease management strategies. Further, the potential predictive value of this index for response to ipilimumab should be investigated in randomized clinical trials.Keywords
Funding Information
- Fondazione Grazia Focacci
- Fondazione Grazia Focacci
This publication has 23 references indexed in Scilit:
- Personalised medicine: Development and external validation of a prognostic model for metastatic melanoma patients treated with ipilimumabEuropean Journal of Cancer, 2015
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II studyAnnals of Oncology, 2015
- Ipilimumab for advanced melanomaMelanoma Research, 2014
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanomaCancer Immunology, Immunotherapy, 2014
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaCancer Immunology, Immunotherapy, 2014
- Single-Center Experience With Ipilimumab in an Expanded Access Program for Patients With Pretreated Advanced MelanomaJournal of Immunotherapy, 2013
- Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survivalAnnals Of Oncology, 2013
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Single‐institution experience with ipilimumab in advanced melanoma patients in the compassionate use settingCancer, 2010